Cat /

Breed profile · FDA CVM July 2026 extract

Manx adverse-event record

Adverse-event filings for Manx (Cat) in the FDA Center for Veterinary Medicine openFDA extract. Browse cat breeds, reactions, and outcomes below.

Verify with FDA CVM →
#171 of 510
by report volume (all breeds)
284
FDA CVM reports on file
11.3%
death-coded share of reports
#40 of 275
by death-coded share (≥50 reports)

How the 284 reports break down

By recorded gender -- every report on file for Manx, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 30 22.5 15 7.5 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Manx drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Manx ranks #171 of 510 by total reports (284) and #40 of 275 by death-coded share (11.3%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#171
This breed, reports of 510
#40
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Manx has 284 reports now versus 277 in that prior snapshot: 7 more (2.5%).

Report change
+7
Death-coded reports
+0
Death-coded share
−0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Manx changes

Total Reports

284

Above-median volume

Deaths Reported

32

of 284 reports

Death-coded share of reports

11.3%

High death-coded share

Avg Age at Report

7.3 yr

4.9 kg avg weight

Breed Safety Scorecard

F (24/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate F
11.3%

Share of reports coded as a fatality

Euthanasia rate F
4.9%

Share of reports resulting in euthanasia

Full recovery rate F
22.9%

Share of reports coded "Recovered/Normal"

5-year trend B+
-18%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Manx death-coded reports 11.3%
Cross-breed median

11.3% of 284 manx reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Manx's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

11% 85th percentile Higher share than 85% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). Below this entry. 20%–25%: 2 indexed breeds (1%). Below this entry. 25%–30%: 3 indexed breeds (1%). Below this entry. 30%–35%: 4 indexed breeds (1%). Below this entry. 35%–40%: 5 indexed breeds (2%). Below this entry. 40%–45%: 6 indexed breeds (2%). Below this entry. 45%–50%: 3 indexed breeds (1%). Below this entry. 50%–55%: 7 indexed breeds (3%). Below this entry. 55%–60%: 7 indexed breeds (3%). Below this entry. 60%–65%: 21 indexed breeds (8%). Below this entry. 65%–70%: 11 indexed breeds (4%). Below this entry. 70%–75%: 15 indexed breeds (5%). Below this entry. 75%–80%: 13 indexed breeds (5%). Below this entry. 80%–85%: 11 indexed breeds (4%). Below this entry. 85%–90%: 12 indexed breeds (4%). Below this entry. 90%–95%: 12 indexed breeds (4%). Below this entry. 95%–100%: 142 indexed breeds (52%). This entry sits in this band. Manx 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 4.9 kg (10.8 lbs)

Top Reported Reactions

Vomiting 45
Lethargy (see also Central nervous system depression in 'Neurological') 33
Emesis 26
Anorexia 23
Lack of efficacy (ectoparasite) - flea 22
Application site hair loss 21
Lack of efficacy - NOS 20
Weight loss 20

Most Referenced Drugs

Spinosad 48
Selamectin 32
Fluralaner Spot-On Solution 25
Frunevetmab 25
Cefovecin 24
Selamectin;Sarolaner 23
Imidacloprid + Moxidectin 17
Nitenpyram 13

Outcome Breakdown

Ongoing
94 (35.2%)
Outcome Unknown
73 (27.3%)
Recovered/Normal
65 (24.3%)
Died
18 (6.7%)
Euthanized
14 (5.2%)
Recovered with Sequela
3 (1.1%)

Gender Distribution

Male 147 (51.8%)
Female 131 (46.1%)
Unknown 4 (1.4%)
Mixed 2 (0.7%)

Reports by Year

Year Reports Trend
2010 12
2011 8
2012 16
2013 21
2014 21
2015 13
2016 16
2017 23
2018 16
2019 20
2020 11
2021 17
2022 13
2023 27
2024 30
2025 14
2026 6

Manx: high death-coded share in the FDA CVM extract

Signature read: Manx's 11.3% death-coded share is in the upper third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Manx sits at #171 of 510 by report volume among all breeds and #17 of 55 among cat breeds, with 284 reports and 32 (11.3%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #40 of 275. Mean age at report: 7.3 years, average weight 4.9 kg (10.8 lbs).

Top reported signs: Vomiting (45), Lethargy (see also Central nervous system depression in 'Neurological') (33), Emesis (26). Most-referenced drug: Spinosad (48 reports), followed by Selamectin (32) and Fluralaner Spot-On Solution (25).

Outcome coding on 267 status-recorded reports is dominated by Ongoing (35.2%). Annual submissions ranged 6-2,026 across 17 years on file.

Cat Breeds With a Similar Report Volume

Showing 6 of 54 cat breeds in our dataset, ranked by closest report volume.

Mixed (Cat)
298 reports · 10.7% death-coded
American Curl Shorthair
228 reports · 3.5% death-coded
Abyssinian cat
201 reports · 9.5% death-coded
Norwegian Forest
193 reports · 5.7% death-coded
Sphynx
184 reports · 13.6% death-coded
Burmese
158 reports · 11.4% death-coded

Nationwide breeds with similar profiles

Two openFDA-derived peer sets for Manx, both outside the Cat family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (11.3% death-coded here).

Collie - Smooth-haired 11.3% · Dog Quarter Horse 11.1% · Horse Percheron 11.5% · Horse Pony (unspecified) 11.9% · Horse

What to do with this cat

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Manx? ▼
There are 284 adverse event reports involving Manx in the FDA database, of which 32 were death-coded (11.3% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Manx ranks #171 of 510 by report volume among all breeds PlainBreed indexes (#17 of 55 among cat breeds).
Where does Manx sit among other breeds in PlainBreed's corpus? ▼
According to FDA CVM report volume, Manx is #171 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Cat, it is #17 of 55. Among breeds with at least 50 reports, its death-coded share ranks #40 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Manx? ▼
The most commonly reported adverse reactions for Manx are Vomiting (45 reports), Lethargy (see also Central nervous system depression in 'Neurological') (33 reports), Emesis (26 reports), Anorexia (23 reports), Lack of efficacy (ectoparasite) - flea (22 reports).
What drugs are most frequently associated with Manx adverse events? ▼
The drugs most frequently referenced in Manx adverse event reports are Spinosad (48 reports), Selamectin (32 reports), Fluralaner Spot-On Solution (25 reports), Frunevetmab (25 reports), Cefovecin (24 reports).
What is the average age of Manx in adverse event reports? ▼
The average age of Manx at the time of adverse event reports is 7.3 years, with an average weight of 4.9 kg (10.8 lbs).

Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Manx (Cat), extract as of July 2026 extract. 284 reports · 32 death-coded (11.3% of reports, not a mortality rate) · #171 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →